$13.62
1.94%
NYSE, Sep 18, 04:06 pm EDT. Closed.
ISIN
VGG111961055
Symbol
BHVN

Biohaven Pharmaceutical Holding Company Ltd. Target price 2026 - Analyst rating & recommendation

Biohaven Pharmaceutical Holding Company Ltd. Classifications & Recommendation

Buy
78%
Hold
17%
Sell
4%

Biohaven Pharmaceutical Holding Company Ltd. Price Target

Target Price $20.91
Price $13.62
Potential
Number of Estimates 17
17 Analysts have issued a price target Biohaven Pharmaceutical Holding Company Ltd. 2027 . The average Biohaven Pharmaceutical Holding Company Ltd. target price is $20.91. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 23 analysts: 18 Analysts recommend Biohaven Pharmaceutical Holding Company Ltd. to buy, 4 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biohaven Pharmaceutical Holding Company Ltd. stock has an average upside potential 2027 of . Most analysts recommend the Biohaven Pharmaceutical Holding Company Ltd. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -6.86 -3.33
26.08% 51.46%
P/E negative

19 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast for earnings per share. The average Biohaven Pharmaceutical Holding Company Ltd. EPS is

$-3.33
unlock
. This is
14.40% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-2.85 26.74%
unlock
, the lowest is
$-3.38 13.11%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-6.86 26.08%
2026
$-3.33 51.46%
unlock
2027
$-2.61 21.62%
unlock
2028
$-2.15 17.62%
unlock
2029
$-0.68 68.37%
unlock
2030
$1.52 323.53%
unlock
2031
$5.17 240.13%
unlock
2032
$9.63 86.27%
unlock
2033
$13.52 40.39%
unlock

P/E ratio

Current -3.50 88.26%
2026
-4.09 16.81%
unlock
2027
-5.22 27.63%
unlock
2028
-6.34 21.46%
unlock
2029
-19.93 214.35%
unlock
2030
8.99 145.11%
unlock
2031
2.63 70.75%
unlock
2032
1.41 46.39%
unlock
2033
1.01 28.37%
unlock

Current Biohaven Pharmaceutical Holding Company Ltd. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Sep 10 2026
RBC Capital
Locked
Locked
Locked Sep 08 2026
Morgan Stanley
Locked
Locked
Locked Aug 12 2026
RBC Capital
Locked
Locked
Locked Aug 11 2026
B of A Securities
Locked
Locked
Locked Jun 29 2026
HC Wainwright & Co.
Locked
Locked
Locked May 26 2026
Morgan Stanley
Locked
Locked
Locked May 13 2026
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 10 2026
Locked
RBC Capital:
Locked
Locked
Sep 08 2026
Locked
Morgan Stanley:
Locked
Locked
Aug 12 2026
Locked
RBC Capital:
Locked
Locked
Aug 11 2026
Locked
B of A Securities:
Locked
Locked
Jun 29 2026
Locked
HC Wainwright & Co.:
Locked
Locked
May 26 2026
Locked
Morgan Stanley:
Locked
Locked
May 13 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today